Rifaximin treatment for reduction of risk of overt hepatic encephalopathy recurrence

Therapeutic Advances in Gastroenterology

Volumn 4, Issue 3, 2011, Pages 199-206

  Flamm, Steven L ^a  

^a NORTHWESTERN UNIVERSITY   (United States)

Author keywords

Ammonia; Cirrhosis; Hepatic encephalopathy; Lactulose; Rifaximin

Indexed keywords

AMMONIA; LACTULOSE; METRONIDAZOLE; NEOMYCIN; RIFAXIMIN;

CLINICAL FEATURE; DRUG APPROVAL; DRUG TOLERABILITY; DRUG USE; GASTROINTESTINAL SYMPTOM; HEPATIC ENCEPHALOPATHY; HUMAN; MULTICENTER STUDY (TOPIC); NEPHROTOXICITY; NEUROTOXICITY; OTOTOXICITY; PRIORITY JOURNAL; RANDOMIZED CONTROLLED TRIAL (TOPIC); RECURRENT DISEASE; REVIEW; RISK REDUCTION; SYMPTOM;

EID: 80052305956     PISSN: 1756283X     EISSN: 17562648     Source Type: Journal    
DOI: 10.1177/1756283X11401774     Document Type: Review

References (25)

1. Als-Nielsen B. Gluud L.L. Gluud C. (2004) Non-absorbable disaccharides for hepatic encephalopathy: systematic review of randomized trials. BMJ 328: 1046–1046.
2. Bajaj J.S. Sanyal A.J. Bell D. Gilles H. Heuman D.M. (2010) Predictors of the recurrence of hepatic encephalopathy in lactulose-treated patients. Ailment Pharmacol Ther 31: 1012–1017.
3. Bass N.M. Mullen K.D. Sanyal A. Poordad F. Neff G. Leevy C.B. et al (2010) Rifaximin treatment in hepatic encephalopathy. N Engl J Med 362: 1071–1081.
4. Bucci L. Palmieri G.C. (1993) Double-blind, double-dummy comparison between treatment with rifaximin and lactulose in patients with medium to severe degree hepatic encephalopathy. Curr Med Res Opin 13: 109–118.
5. Conn H.O. (1994) Hepatic encephalopathy: Syndromes and therapies. In: Ed. Conn H.O. Bircher J. (eds). Quantifying the severity of hepatic encephalopathy, Medi-ed Press: Bloomington, IL, 373–383.
6. Conn H.O. Leevy C.M. Vlahcevic Z.R. Rodgers J.B. Maddrey W.C. Seef L. et al (1977) Comparison of lactulose and neomycin in the treatment of chronic portal systemic encephalopathy. A double blind controlled trial. Gastroenterology 72: 573–583.
7. Conn H.O. Lieberthal M.M. (1979) The Hepatic Coma Syndromes and Lactulose, Williams & Wilkins: Baltimore, MD.
8. Cordoba J. Blei A. (2007) Diseases of liver. In: Ed. Schiff E.R. Sorell M.F. Maddrey W.C. (eds). Hepatic Encephalopathy, Lippincott Williams and Wilkins: Philadelphia, PA, 569–599.
9. Ferenci P. Lockwood A. Mullen K. Tarter R. Weissenborn K. Blei A.T. (1998) Hepatic encephalopathy–definition, nomenclature, diagnosis, and quanitification: final report of the working party at the 11th World Congress of Gastroenterology, Vienna, 1998. Hepatology 35: 716–721.
10. Fritz E. Hammer H.F. Lipp R.W. Hogenauer C. Stauber R. Hammer J. (2005) Effects of lactulose and polyethylene glycol on colonic transit. Ailment Pharmacol Ther 21: 259–268.
11. Keiding S. Sorenson M. Bender D. Munk O.L. Ott P. Vilstrup H. (2006) Brain metabolism of 13N-ammonia during acute hepatic encephalopathy in cirrhosis measured by position emission tomography. Hepatology 43: 42–50.
12. Leevy C.B. Phillips J.A. (2007) Hospitalizations during the use of rifaximin versus lactulose for the treatment of hepatic encephalopathy. Dig Dis Sci 52: 737–741.
13. Loguercio C. Federico A. de Girolamo V. Ferrieri A. Del Vecchio Blanco C. (2003) Cyclic treatment of chronic hepatic encephalopathy with rifaximin. Results of a double-blind clinical study. Minerva Gastroenterol Dietol 49: 53–62.
14. Mas A. Rodes J. Sunyer L. Rodrigo L. Planas R. Vargas V. et al (2003) Comparison of rifaximin and lactitol in the treatment of acute hepatic encephalopathy: Results of a randomized, double-blind, double-dummy, controlled clinical trial. J Hepatol 38: 51–58.
15. Massa P. Vallerino E. Dodero M. (1993) Treatment of hepatic encephalopathy with rifaximin: double-blind, double dummy study versus lactulose. Eur J Clin Res 4: 7–18.
16. Mortensen P.B. (1992) The effect of oral-administered lactulose on colonic nitrogen metabolism and excretion. Hepatology 16: 1350–1356.
17. Mullen K.D. (2007) Pathogenesis, clinical manifestation, and diagnosis of hepatic encephalopathy. Semin Liver Dis 27(Suppl. 2): 10–17.
18. Neff G.W. Kemmer N. Zacharias V.C. Kaiser T. Duncan C. McHenry R. et al (2006) Analysis of hospitalizations comparing rifaximin versus lactulose in the management of hepatic encephalopathy. Transplant Proc 38: 3552–3555.
19. Pedretti G. Calzetti C. Missale G. Fiaccadori F. (1991) Rifaximin versus neomycin on hyperammoniemia in chronic portal systemic encephalopathy of cirrhotics. A double-blind, randomized trial. Ital J Gastroenterol 23: 175–178.
20. Poordad F.F. (2007) Review article: The burden of hepatic encephalopathy. Ailment Pharmacol Ther 25: 3–9.
21. Sama C. Morselli-Labate A.M. Pianta P. Lambertini L. Berardi S. Martini G. (2004) Clinical effects of rifaximin in patients with hepatic encephalopathy intolerant or nonresponsive to previous lactulose treatment: An open labeled study. Curr Ther Res 65: 413–422.
22. Shawcross D.L. Davies N.A. Williams R. Jalan R. (2004) Systemic inflammatory response exacerbates the neuropsychological effects of induced hyperammonemia in cirrhosis. J Hepatol 40: 247–254.
23. Strauss E. Tramote R. Silva E.P. Caly W.R. Honain N.Z. Maffei R.A. et al (1992) Double-blind randomized clinical trial comparing neomycin and placebo in the treatment of exogenous hepatic encephalopathy. Hepatogastroenterology 39: 542–545.
24. Williams R. Bass N. (2005) Rifaximin, a nonabsorbed oral antibiotic, in the treatment of hepatic encephalopathy: Antimicrobial activity, efficacy, and safety. Rev Gastroenterol Disord 5(Suppl): 10–18.
25. Williams R. James O.F. Warnes T.W. Morgan M.Y. (2000) Evaluation of the efficacy and safety of rifaximin in the treatment of hepatic encephalopathy: A double-blind, randomized, dose-finding multi-centre study. Eur J Gastroenterol Hepatol 12: 203–208.